X |
Filing Date |
Trade Date |
Ticker |
Company Name | Insider Name | Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2026-08-10 | TAK | Takeda Pharmaceutical Co Ltd | Farajallah Awny Samaan Botros | Chief Medical Officer | S - Sale | $17.10 | -14,006 | 116,177 | -11% | -$239,503 | ||||||
2026-08-10 | TAK | Takeda Pharmaceutical Co Ltd | Ibrahim Ramy Riad Ahmed | Pres, PDT BU | S - Sale | $17.10 | -7,277 | 102,588 | -7% | -$124,437 | ||||||
2026-08-10 | TAK | Takeda Pharmaceutical Co Ltd | Pacheco Rhonda Janice | Pres, U.S. Business Unit | S - Sale | $17.10 | -16,901 | 182,507 | -8% | -$289,007 | ||||||
2026-08-10 | TAK | Takeda Pharmaceutical Co Ltd | Duprey Lauren Rusckowski | Chief Transformation Officer | S - Sale | $17.10 | -47,586 | 226,057 | -17% | -$813,721 | ||||||
2026-08-10 | TAK | Takeda Pharmaceutical Co Ltd | Plump Andrew Stewart | Pres, R, D | S - Sale | $17.10 | -165,393 | 1,047,876 | -14% | -$2,828,220 | ||||||
2026-08-10 | TAK | Takeda Pharmaceutical Co Ltd | Pignagnoli Agosti Marcello | Head, Strat., Port. Dev | S - Sale | $17.10 | -22,957 | 176,977 | -11% | -$392,565 | ||||||
2026-08-10 | TAK | Takeda Pharmaceutical Co Ltd | Bitetti Teresa Marie | Pres, OBU | S - Sale | $17.10 | -50,012 | 252,010 | -17% | -$855,205 | ||||||
| D | 2026-08-03 | HEPA | Hepion Pharmaceuticals, Inc. | Stetz Gary S. II | Dir | P - Purchase | $0.05 | +500,000 | 500,000 | New | +$25,000 | |||||
2026-08-10 | TAK | Takeda Pharmaceutical Co Ltd | Shannon Elaine Mary | Pres, Global Supply, Quality | S - Sale | $17.10 | -3,978 | 63,333 | -6% | -$68,024 | ||||||
| D | 2026-08-03 | HEPA | Hepion Pharmaceuticals, Inc. | Stetz Gary S. | Interim CEO | P - Purchase | $0.05 | +2,000,000 | 3,250,000 | +160% | +$100,000 | |||||
2026-08-10 | TAK | Takeda Pharmaceutical Co Ltd | Ricci Gabriele | Chief Data, Tech. Officer | S - Sale | $17.10 | -25,088 | 171,654 | -13% | -$429,005 | ||||||
| D | 2026-08-03 | HEPA | Hepion Pharmaceuticals, Inc. | Purcell Michael J. | Dir | P - Purchase | $0.05 | +2,000,000 | 3,250,000 | +160% | +$100,000 | |||||
| D | 2026-08-03 | HEPA | Hepion Pharmaceuticals, Inc. | Appajosyula Sireesh | COO | P - Purchase | $0.05 | +2,000,000 | 3,250,000 | +160% | +$100,000 | |||||
| D | 2026-08-03 | HEPA | Hepion Pharmaceuticals, Inc. | Lopriore Vincent S | Exec COB | P - Purchase | $0.05 | +10,000,000 | 30,500,000 | +49% | +$500,000 | |||||
2026-08-10 | TAK | Takeda Pharmaceutical Co Ltd | Greenway Nicola Deidre Petal | CHRO | S - Sale | $17.10 | -6,774 | 53,029 | -11% | -$115,835 | ||||||
2026-08-10 | TAK | Takeda Pharmaceutical Co Ltd | Kim Julie So-Young | Pres, CEO | S - Sale | $17.10 | -89,090 | 391,489 | -19% | -$1,523,439 | ||||||
2026-08-10 | TAK | Takeda Pharmaceutical Co Ltd | Platford Giles Richard | Pres, IBU | S - Sale | $17.10 | -31,083 | 315,838 | -9% | -$531,519 | ||||||
2026-08-10 | TAK | Takeda Pharmaceutical Co Ltd | Furney Natalie Anne Marie | Global GC | S - Sale | $17.10 | -30,868 | 204,298 | -13% | -$527,843 | ||||||
| D | 2026-08-11 | SGMT | Sagimet Biosciences Inc. | Kemble George | Dir | S - Sale+OE | $9.95 | -20,206 | 62,161 | -25% | -$201,147 | |||||
| D | 2026-08-10 | MLYS | Mineralys Therapeutics, Inc. | Rodman David Malcom | Chief Medical Officer | S - Sale+OE | $27.09 | -2,170 | 51,384 | -4% | -$58,785 | |||||
2026-08-11 | PTIX | Protagenic Therapeutics, Inc.New | Armen Garo H | EXEC. CHAIR, PRINCIPAL OFF | P - Purchase | $0.32 | +2,220 | 34,199 | +7% | +$710 | ||||||
| DM | 2026-08-10 | PTGX | Protagonist Therapeutics, Inc | Patel Dinesh V Ph D | Pres, CEO | S - Sale+OE | $148.91 | -100,000 | 523,478 | -16% | -$14,890,799 | |||||
| AD | 2026-07-07 | VERA | Vera Therapeutics, Inc. | Fordyce Marshall | Pres, CEO | S - Sale+OE | $42.30 | -46,250 | 235,244 | -16% | -$1,956,187 | |||||
| AD | 2026-06-23 | VERA | Vera Therapeutics, Inc. | Fordyce Marshall | Pres, CEO | S - Sale+OE | $37.93 | -18,500 | 235,244 | -7% | -$701,769 | |||||
| AD | 2026-05-12 | VERA | Vera Therapeutics, Inc. | Fordyce Marshall | Pres, CEO | S - Sale+OE | $36.74 | -18,500 | 235,244 | -7% | -$679,747 | |||||
2026-08-11 | AMPH | Amphastar Pharmaceuticals, Inc. | Prins Richard K | Dir | S - Sale | $20.30 | -7,973 | 29,625 | -21% | -$161,852 | ||||||
| M | 2026-08-10 | ONC | Beone Medicines Ltd. | Oyler John | CEO | S - Sale | $359.12 | -240,810 | 47,362,982 | -1% | -$86,480,472 | |||||
| M | 2026-08-10 | IMNM | Immunome Inc. | Barchas Isaac | Dir | S - Sale | $26.35 | -83,464 | 92,211 | -48% | -$2,198,910 | |||||
2026-08-11 | MIRM | Mirum Pharmaceuticals, Inc. | Bjerkholt Eric | CFO | S - Sale | $99.90 | -6,001 | 36,355 | -14% | -$599,510 | ||||||
| D | 2026-08-10 | INSM | Insmed Inc | Adsett Roger | COO | S - Sale+OE | $133.27 | -239,850 | 98,744 | -71% | -$31,964,810 | |||||
| D | 2026-08-10 | BLSM | Blossomhill Therapeutics, Inc. | Gordon Carl L | Dir | P - Purchase | $16.00 | +625,000 | 2,714,279 | +30% | +$10,000,000 | |||||
2026-08-12 | XERS | Xeris Biopharma Holdings, Inc. | Pieper Steven | See Remarks | S - Sale | $8.50 | -5,000 | 1,361,053 | 0% | -$42,500 | ||||||
| D | 2026-08-10 | BLSM | Blossomhill Therapeutics, Inc. | Orbimed Advisors LLC | Dir | P - Purchase | $16.00 | +625,000 | 2,714,279 | +30% | +$10,000,000 | |||||
| M | 2026-08-10 | RAPP | Rapport Therapeutics, Inc. | Ceesay Abraham | CEO | S - Sale | $47.25 | -51,499 | 588,566 | -8% | -$2,433,176 | |||||
| D | 2026-08-11 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $522.87 | -9,500 | 668,728 | -1% | -$4,967,292 | |||||
2026-08-11 | CRBP | Corbus Pharmaceuticals Holdings, Inc. | Saxena Nishant C | Chief Business Officer | P - Purchase | $9.63 | +2,600 | 77,900 | +3% | +$25,036 | ||||||
| D | 2026-08-10 | CORT | Corcept Therapeutics Inc | Maduck Sean | See Remarks | S - Sale+OE | $114.52 | -1,031 | 119,472 | -1% | -$118,068 | |||||
| D | 2026-08-10 | CORT | Corcept Therapeutics Inc | Guyer William | Chief Development Officer | S - Sale+OE | $113.43 | -16,300 | 3,985 | -80% | -$1,848,890 | |||||
| D | 2026-08-10 | BCAX | Bicara Therapeutics Inc. | Hyep Ivan | CFO | S - Sale+OE | $27.97 | -12,500 | 129,855 | -9% | -$349,591 | |||||
| D | 2026-08-10 | BCAX | Bicara Therapeutics Inc. | Mazumdar Claire | CEO | S - Sale+OE | $27.98 | -10,000 | 362,152 | -3% | -$279,750 | |||||
| D | 2026-08-10 | BCAX | Bicara Therapeutics Inc. | Cohlhepp Ryan | Pres, COO | S - Sale+OE | $27.98 | -18,750 | 181,641 | -9% | -$524,533 | |||||
| D | 2026-08-10 | REGN | Regeneron Pharmaceuticals, Inc. | Guarini Kathryn | Dir | S - Sale+OE | $800.00 | -400 | 603 | -40% | -$320,000 | |||||
| D | 2026-08-10 | ZVRA | Zevra Therapeutics, Inc. | Watton Corey Michael | Dir | S - Sale+OE | $11.25 | -12,300 | 1,800 | -87% | -$138,377 | |||||
| D | 2026-08-10 | REGN | Regeneron Pharmaceuticals, Inc. | Zoghbi Huda Y | Dir | S - Sale+OE | $800.00 | -800 | 1,703 | -32% | -$640,000 | |||||
| M | 2026-08-10 | MRK | Merck & Co., Inc. | Deluca Richard R. | EVP, Pres, Merck Animal Heallt | S - Sale | $131.12 | -45,320 | 110,167 | -29% | -$5,942,369 | |||||
2026-08-11 | AVTX | Avalo Therapeutics, Inc. | Riley Jennifer | Chief Strategy Officer | S - Sale | $19.59 | -2,655 | 37,041 | -7% | -$52,012 | ||||||
| D | 2026-08-10 | AVTX | Avalo Therapeutics, Inc. | Doyle Mittie | Chief Medical Officer | S - Sale+OE | $20.00 | -679 | 51,776 | -1% | -$13,580 | |||||
2026-08-11 | TAK | Takeda Pharmaceutical Co Ltd | Shannon Elaine Mary | Pres, Global Supply, Quality | S - Sale | $17.55 | -20,363 | 67,311 | -23% | -$357,371 | ||||||
2026-08-10 | TAK | Takeda Pharmaceutical Co Ltd | Greenway Nicola Deidre Petal | CHRO | S - Sale | $17.51 | -34,603 | 59,803 | -37% | -$605,778 | ||||||
2026-08-12 | PFE | Pfizer Inc | Bourla Albert | COB, CEO | P - Purchase | $26.34 | +38,000 | 435,555 | +10% | +$1,000,920 | ||||||
2026-08-10 | NXTC | Nextcure, Inc. | Simcere Zaiming, Inc. | Former 10% Owner | S - Sale | $6.16 | -30,000 | 308,636 | -9% | -$184,800 | ||||||
2026-08-10 | ANIP | Ani Pharmaceuticals Inc | Gutwerg Ori | SVP, GENERICS | S - Sale | $77.00 | -3,162 | 75,534 | -4% | -$243,474 | ||||||
2026-08-11 | CYRX | Cryoport, Inc. | Shelton Jerrell | Pres, CEO | S - Sale | $14.91 | -28,800 | 1,201,814 | -2% | -$429,385 | ||||||
| D | 2026-08-07 | BRVE | Braveheart Bio, Inc. | Ah Bio Fund Iv, L.P. | 10% | P - Purchase | $18.00 | +1,100,000 | 10,232,420 | +12% | +$19,800,000 | |||||
| D | 2026-08-10 | MIRM | Mirum Pharmaceuticals, Inc. | Peetz Christopher | CEO | S - Sale+OE | $98.92 | -20,000 | 381,809 | -5% | -$1,978,402 | |||||
| D | 2026-08-07 | BRVE | Braveheart Bio, Inc. | Chimovits Erez | Dir, 10% | P - Purchase | $18.00 | +1,940,000 | 273,333 | -116% | +$34,920,000 | |||||
| D | 2026-08-07 | BRVE | Braveheart Bio, Inc. | Orbimed Advisors LLC | Dir, 10% | P - Purchase | $18.00 | +1,940,000 | 273,333 | -116% | +$34,920,000 | |||||
| D | 2026-08-10 | DNTH | Dianthus Therapeutics, Inc. /De/ | McGeorge Anne | Dir | S - Sale+OE | $109.01 | -7,750 | 0 | -100% | -$844,822 | |||||
| D | 2026-08-10 | DNTH | Dianthus Therapeutics, Inc. /De/ | Read Simon | Dir | S - Sale+OE | $109.55 | -2,777 | 0 | -100% | -$304,232 | |||||
| DM | 2026-08-07 | DNTH | Dianthus Therapeutics, Inc. /De/ | Veness Adam M | SVP, GC, Sec. | S - Sale+OE | $110.44 | -20,000 | 0 | -100% | -$2,208,833 | |||||
| D | 2026-08-07 | AMPH | Amphastar Pharmaceuticals, Inc. | Peters William J | CFO, EVP, Treasurer | S - Sale+OE | $22.48 | -8,180 | 172,846 | -5% | -$183,886 | |||||
| E | 2026-08-10 | LLY | Eli Lilly & Co | Zakrowski Donald A | SVP, Finance, CAO | S - Sale | $0.59 | -2,000 | 3,261 | -38% | -$1,185 | |||||
| D | 2026-08-10 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $530.11 | -9,500 | 668,728 | -1% | -$5,036,073 | |||||
2026-08-10 | LYEL | Lyell Immunopharma, Inc. | Bulis Veronica Sanchez | VP, Corporate Controller | S - Sale | $14.34 | -621 | 14,799 | -4% | -$8,905 | ||||||
2026-08-10 | LYEL | Lyell Immunopharma, Inc. | Lee Gary K. | Chief Scientific Officer | S - Sale | $14.34 | -131 | 17,677 | -1% | -$1,879 | ||||||
2026-08-10 | LYEL | Lyell Immunopharma, Inc. | Hill Stephen J. | COO | S - Sale | $14.34 | -89 | 17,805 | 0% | -$1,276 | ||||||
2026-08-10 | LYEL | Lyell Immunopharma, Inc. | Seely Lynn | Pres, CEO | S - Sale | $14.34 | -390 | 73,488 | -1% | -$5,593 | ||||||
| D | 2026-08-07 | SYRE | Spyre Therapeutics, Inc. | Albers Jeffrey W. | Dir | S - Sale+OE | $104.53 | -23,000 | 9,360 | -71% | -$2,404,190 | |||||
2026-08-07 | MNKD | Mannkind Corp | Binder Steven B. | Dir | S - Sale | $4.06 | -39,051 | 785,867 | -5% | -$158,547 | ||||||
| D | 2026-08-10 | LTGO | Latigo Biotherapeutics, Inc. | Foresite Capital Management V, LLC | 10% | P - Purchase | $18.00 | +140,000 | 3,414,544 | +4% | +$2,520,000 | |||||
| D | 2026-08-10 | LTGO | Latigo Biotherapeutics, Inc. | Tananbaum James B. | Dir, 10% | P - Purchase | $18.00 | +140,000 | 3,414,544 | +4% | +$2,520,000 | |||||
| M | 2026-08-06 | TRDA | Entrada Therapeutics, Inc. | Parmar Kush | Dir | S - Sale | $6.95 | -155,255 | 3,784,650 | -4% | -$1,078,937 | |||||
| M | 2026-08-06 | TRDA | Entrada Therapeutics, Inc. | 5Am Ventures V, L.P. | 10% | S - Sale | $6.88 | -62,811 | 3,877,094 | -2% | -$431,829 | |||||
| M | 2026-08-06 | NATR | Natures Sunshine Products Inc | Prescott Group Capital Management, L.L.C. | 10% | P - Purchase | $16.40 | +141,389 | 1,924,486 | +8% | +$2,318,912 | |||||
2026-08-10 | BLSM | Blossomhill Therapeutics, Inc. | Schmid John P. | Dir | P - Purchase | $16.00 | +6,000 | 6,000 | New | +$96,000 | ||||||
| D | 2026-08-10 | BLSM | Blossomhill Therapeutics, Inc. | Chen Bihua | Dir, 10% | P - Purchase | $16.00 | +312,500 | 3,614,034 | +9% | +$5,000,000 | |||||
| D | 2026-08-10 | BLSM | Blossomhill Therapeutics, Inc. | Keyes Jason A | CFO | P - Purchase | $16.00 | +700 | 700 | New | +$11,200 | |||||
| DM | 2026-08-07 | BLSM | Blossomhill Therapeutics, Inc. | Liptak Vincent Paul | GC | P - Purchase | $15.89 | +4,700 | 134,099 | +4% | +$74,700 | |||||
| D | 2026-08-10 | CYTK | Cytokinetics Inc | Blum Robert I | Pres, CEO | S - Sale+OE | $76.76 | -7,500 | 381,986 | -2% | -$575,700 | |||||
| D | 2026-08-07 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $531.38 | -9,500 | 668,728 | -1% | -$5,048,137 | |||||
2026-08-07 | CRBP | Corbus Pharmaceuticals Holdings, Inc. | Cohen Yuval | CEO | S - Sale | $10.08 | -17,000 | 157,316 | -10% | -$171,396 | ||||||
2026-08-07 | CRBP | Corbus Pharmaceuticals Holdings, Inc. | Moran Sean F. | CFO | S - Sale | $10.08 | -12,000 | 84,694 | -12% | -$120,971 | ||||||
2026-08-06 | MRK | Merck & Co., Inc. | Deluca Richard R. | EVP, Pres, Merck Animal Heallt | S - Sale | $130.38 | -6,050 | 155,487 | -4% | -$788,773 | ||||||
| E | 2026-08-07 | LLY | Eli Lilly & Co | Hakim Anat | EVP, GC, Secretary | S - Sale | $0.24 | -5,000 | 50,562 | -9% | -$1,190 | |||||
| D | 2026-08-07 | ELAN | Elanco Animal Health Inc | Vanhimbergen Robert M | EVP, CFO | P - Purchase | $23.08 | +4,200 | 137,516 | +3% | +$96,926 | |||||
2026-08-07 | ELAN | Elanco Animal Health Inc | Herendeen Paul | Dir | P - Purchase | $23.69 | +10,000 | 111,687 | +10% | +$236,850 | ||||||
| M | 2026-08-06 | IMNM | Immunome Inc. | Barchas Isaac | Dir | S - Sale | $26.06 | -36,088 | 175,675 | -17% | -$940,453 | |||||
2026-08-07 | PRTA | Prothena Corp Public Ltd Co | Scully William P | 10% | P - Purchase | $8.62 | +37,500 | 925,500 | +4% | +$323,220 | ||||||
2026-08-06 | PTIX | Protagenic Therapeutics, Inc.New | Armen Garo H | EXEC. CHAIR, PRINCIPAL OFF | P - Purchase | $0.22 | +685 | 31,979 | +2% | +$151 | ||||||
2026-08-07 | CTTH | Ctt Pharmaceutical Holdings, Inc. | Ctt Pharmaceutical Holdings, Inc. | CEO | P - Purchase | $0.07 | +7,700 | 9,353,656 | 0% | +$501 | ||||||
2026-08-05 | TEVA | Teva Pharmaceutical Industries Ltd | Zaks Tal Zvi | Dir | S - Sale | $34.87 | -17 | 73,247 | 0% | -$593 | ||||||
| DM | 2026-08-05 | AXSM | Axsome Therapeutics, Inc. | Tabuteau Herriot | CEO, 10% | S - Sale+OE | $212.19 | -49,664 | 7,351,729 | -1% | -$10,538,305 | |||||
| D | 2026-08-07 | DNTH | Dianthus Therapeutics, Inc. /De/ | Garcia Marino | CEO, Pres | S - Sale+OE | $108.11 | -166,000 | 65,292 | -72% | -$17,945,451 | |||||
| DM | 2026-08-05 | ACAD | Acadia Pharmaceuticals Inc | Schneyer Mark C. | EVP, CFO | S - Sale+OE | $29.16 | -20,141 | 67,828 | -23% | -$587,242 | |||||
2026-08-05 | JNJ | Johnson & Johnson | Duato Joaquin | CEO, COB | S - Sale | $258.15 | -48,480 | 307,837 | -14% | -$12,515,010 | ||||||
| D | 2026-08-06 | JNJ | Johnson & Johnson | Forminard Elizabeth | EVP, GC | S - Sale+OE | $257.00 | -15,918 | 16,994 | -48% | -$4,090,960 | |||||
| D | 2026-08-06 | IRON | Disc Medicine, Inc. | Khara Rahul | GC | S - Sale+OE | $80.00 | -5,000 | 52,324 | -9% | -$400,000 | |||||
| D | 2026-08-07 | BRVE | Braveheart Bio, Inc. | Forbion Growth Opportunities Fund III Cooperatief U.A. | 10% | P - Purchase | $18.00 | +3,600,000 | 21,826,024 | +20% | +$64,800,000 | |||||
2026-08-06 | PGEN | Precigen, Inc. | Shah Rutul R | COO | S - Sale | $6.86 | -32,739 | 465,012 | -7% | -$224,590 | ||||||
| D | 2026-08-07 | BRVE | Braveheart Bio, Inc. | Rickey James Paul | CFO | P - Purchase | $18.00 | +27,777 | 703,575 | +4% | +$499,986 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |